Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands
Open accessThe DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
There is little evidence on the costs associated with the route of administration of oncology drugs. We investigated time and resource use for hospitals and patients and compared healthcare and societal costs for intravenous (IV) and subcutaneous (SC) administration of trastuzumab and rituximab. Data for the preparation and administration of both drugs were collected at the hospital pharmacy and at the oncology day care unit. Patients completed a questionnaire for obtaining information on societal costs (productivity losses, informal care and traveling expenses). A total of 126 patients were recruited in six hospitals; 82 received trastuzumab (37 IV and 45 SC) and 44 received rituximab (23 IV and 21 SC). The costs per administration (including societal cost but excluding drug costs) were &OV0556;167 and &OV0556;264 for IV and &OV0556;76 and &OV0556;146 for SC trastuzumab and rituximab, respectively. The costs for SC administration were lower in all categories. The largest cost component was related to time spent at the day care unit (overhead costs). This resulted in savings of &OV0556;47 for SC trastuzumab and &OV0556;69 for SC rituximab. The costs related to time of healthcare professionals was &OV0556;9 lower for both drugs. The costs for consumables resulted in another &OV0556;12 savings. Societal costs were &OV0556;22 lower for SC trastuzumab and &OV0556;28 lower for SC rituximab. Although administration costs are relatively a small part of the total costs, important savings can be generated by switching to an SC route of administration especially because a large number of patients receive oncology drugs and patients receive more than one administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Administration time for trastuzumab was reported in five publications, of which four directly measured time [49, 53, 54, 62]; one publication reported estimated time from drug delivery software [51], which was found to be consistent with the other four publications.”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [53]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Based on direct measurements, active HCP time was 13–92 min (IV) versus 7–30 min (SC); a difference of 6–62 min [50, 53, 59, 62–65, 67].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“SC administration costs were also lower for consumables [49, 53, 54, 57, 59, 61–64, 67], drug wastage [67], use of central venous access devices [86], overheads [87], nursing and pharmacy supplies [84], and avoiding catheter implantation surgeries [54] compared with administration costs for IV in all publications that reported such information.”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [53]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“and 32–107 min in the three publications in which loading/subsequent doses were not specified [49, 53, 62].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [53]
Experimental — accuracy not yet measuredIn the citing paper
“Thirteen publications covering ten countries reported total direct medical costs for IV versus SC administration [51, 53, 54, 59, 60, 63, 64, 69, 82–86], which included non-drug costs for preparation, administration, HCP time and consumables, and savings related to reduced drug wastage or administered dose.”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [53]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., Forman, D., & Bray, F. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.027 · Cited by 5,263
Ismael, G., Hegg, R., Muehlbauer, S., Heinzmann, D., Lum, B., Kim, S.-B., Pienkowski, T., Lichinitser, M., Semiglazov, V., Melichar, B., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70329-7 · Cited by 351
Comparing methodologies for the cost estimation of hospital services
Tan, S. S., Rutten, F. F. H., van Ineveld, B. M., Redekop, W. K., & Hakkaart-van Roijen, L. (2009) · The European Journal of Health Economics · doi:10.1007/s10198-008-0101-x · Cited by 269
Update of the Dutch manual for costing studies in health care
Kanters, T. A., Bouwmans, C. A. M., van der Linden, N., Tan, S. S., & Hakkaart-van Roijen, L. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187477 · Cited by 260
Self-citationPivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70383-8 · Cited by 230
The Use of the Bootstrap Statistical Method for the Pharmacoeconomic Cost Analysis of Skewed Data
Desgagné, A., Castilloux, A.-M., Angers, J.-F., & Le Lorier, J. (1998) · PharmacoEconomics · doi:10.2165/00019053-199813050-00002 · Cited by 180
Rummel, M., Kim, T. M., Aversa, F., Brugger, W., Capochiani, E., Plenteda, C., Re, F., Trask, P., Osborne, S., Smith, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw685 · Cited by 154
Davies, A., Merli, F., Mihaljevic, B., Siritanaratkul, N., Solal-Céligny, P., Barrett, M., Berge, C., Bittner, B., Boehnke, A., McIntyre, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70005-1 · Cited by 114
Jackisch, C., Kim, S.-B., Semiglazov, V., Melichar, B., Pivot, X., Hillenbach, C., Stroyakovskiy, D., Lum, B. L., Elliott, R., Weber, H. A., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu524 · Cited by 114
De Cock, E., Pivot, X., Hauser, N., Verma, S., Kritikou, P., Millar, D., & Knoop, A. (2016) · Cancer Medicine · doi:10.1002/cam4.573 · Cited by 112
Research works printed but not linked: 1
- Ponzetti, 2016, Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 italian hospitals based on a systematic survey, Clinicoecon Outcomes Res, 8, 227
Cited by
Dutta, B., Huys, I., Vulto, A. G., & Simoens, S. (2019) · BioDrugs · doi:10.1007/s40259-019-00395-w · Cited by 143
Johnson, M. L., Braiteh, F., Grilley‐Olson, J. E., Chou, J., Davda, J. P., Forgie, A. J., Li, R., Jacobs, I. A., Kazazi, F., & Hu‐Lieskovan, S. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0836 · Cited by 77
McCloskey, C., Ortega, M. T., Nair, S., Garcia, M. J., & Manevy, F. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00361-3 · Cited by 66
“2 Administration Time Administration time for trastuzumab was reported in five publications, of which four directly measured time [49, 53, 54, 62]; one publication reported estimated time from drug delivery software [51], which was found to be consistent with the other four publications.”
BackgroundMethodResultInfluentialShimizu, T., Nakajima, T. E., Yamamoto, N., Yonemori, K., Koyama, T., Kondo, S., Sunakawa, Y., Izawa, N., Horie, Y., Xiang, S., et al. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01287-7 · Cited by 51
Thielen, F. W. F., van Dongen‐Leunis, A., Arons, A. M. M., Ladestein, J. R., Hoogerbrugge, P. M., & Groot, C. A. U. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13427 · Cited by 42
Metadata
- Authors
- Franken, M. G., Kanters, T. A., Coenen, J. L., de Jong, P., Koene, H. R., Lugtenburg, P. J., Jager, A., & Uyl-de Groot, C. A.
- Affiliations
- Erasmus University Rotterdam (NL)
- Isala (NL)
- St. Antonius Ziekenhuis (NL)
- Erasmus MC Cancer Institute (NL)
- Corresponding author
- Franken, Margreet G.
- Venue
- Anti-Cancer Drugs
- Published
- 2018-09
- Volume
- 29
- Issue
- 8
- Pages
- 791-801
- ISSN
- 0959-4973 (ISSN-L)
- OpenAlex
- W2805001001
- Cited by
- 37
- References
- 21
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 6 · 2023: 2 · 2022: 8 · 2021: 6 · 2020: 3 · 2019: 3
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- green
- pure.eur.nl
- Licence
- other-oa
- Locations
- Anti-Cancer Drugs (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Funders
- Roche Nederland
- Erasmus Medisch Centrum
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Safe Handling of Antineoplastic Drugs
- Keywords
- route of administration, subcutaneous administration, intravenous administration, trastuzumab, rituximab, oncology drugs, health care costs, social costs, productivity loss, informal care, hospital pharmacy, cost reduction
- MeSH terms
- Trastuzumab, Rituximab, Antineoplastic Agents, Immunological, Aged, Female, Humans, Infusions, Intravenous, Injections, Subcutaneous, Male, Middle Aged, Netherlands, Retrospective Studies, Drug Costs, Infusions, Subcutaneous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands. https://app.cochat.ai/papers/10.1097/cad.0000000000000648
- The paper
- Franken, M. G., Kanters, T. A., Coenen, J. L., de Jong, P., Koene, H. R., Lugtenburg, P. J., Jager, A., & Uyl-de Groot, C. A. (2018). Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands. Anti-Cancer Drugs. https://doi.org/10.1097/cad.0000000000000648
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.